Key facts
- Anocca’s last known valuation is $110.2M (May 2023).
- It has raised $210.6M; the latest was Later Stage VC ($45.8M) in Aug 2025.
- Notable investors include European Union, Nidoco, Ramsbury Invest, AMF, Harald Mix — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Anocca
- ·The full record, as it builds
Funding rounds
No funding rounds for Anocca are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Anocca
Developer of drugs and immunotherapies intended to unlock the therapeutic potential of T-cell immunity. The company does precise analysis of T-cell biology that is required to deliver a range of therapeutics that specifically harness or manipulate T-cell immunity in a number of disease areas, including cancer, helping the life sciences sector to develop a range of therapies and vaccination strategies.
- Sector
- Healthcare
- HQ
- Sodertalje, Sweden
- Founded
- 2014
- Employees
- 100
- Website
- anocca.com/
- Ownership
- Privately Held (backing)
Anocca doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Anocca shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Anocca in its N-PORT filings yet. We sweep new filings monthly.